Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Depreciation & Amortization (CF) (2016 - 2025)

Tandem Diabetes Care's Depreciation & Amortization (CF) history spans 13 years, with the latest figure at $4.5 million for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) rose 5.89% year-over-year to $4.5 million; the TTM value through Dec 2025 reached $17.7 million, up 6.38%, while the annual FY2025 figure was $17.7 million, 6.38% up from the prior year.
  • Depreciation & Amortization (CF) reached $4.5 million in Q4 2025 per TNDM's latest filing, roughly flat from $4.5 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $4.5 million in Q4 2025 to a low of $3.4 million in Q1 2023.
  • Average Depreciation & Amortization (CF) over 5 years is $3.9 million, with a median of $4.0 million recorded in 2023.
  • Peak YoY movement for Depreciation & Amortization (CF): skyrocketed 90.44% in 2021, then decreased 6.39% in 2023.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $3.5 million in 2021, then increased by 3.44% to $3.6 million in 2022, then increased by 10.71% to $4.0 million in 2023, then rose by 5.31% to $4.2 million in 2024, then increased by 5.89% to $4.5 million in 2025.
  • Per Business Quant, the three most recent readings for TNDM's Depreciation & Amortization (CF) are $4.5 million (Q4 2025), $4.5 million (Q3 2025), and $4.4 million (Q2 2025).